A new study in the journal Drug and Alcohol Dependence Reports found that adults with disabilities received AUD diagnoses at more than three times the rate of adults without disabilities between 2016-2023. Adults with serious mental illness, such as severe depression, schizophrenia, and bipolar disorder, had the highest rates of AUD at more than 10 times the rate of non-disabled adults. Adults with acquired brain injuries, such as traumatic brain injury and stroke, had the second-highest rates of AUD, at over 5 times the rate of non-disabled adults. Importantly, adults with all types of disabilities had higher rates of AUD than adults without disabilities. 

In a first-of-its-kind clinical trial, U.S. researchers have found that people with agitation and dementia in late life who took a special medical formulation of two active ingredients found in marijuana – THC and CBD – had significantly less agitation compared to people who received a placebo. The primary findings of the study were presented July 14, 2026, at the Alzheimer’s Association International Conference in London.

New research out of VCU Massey Comprehensive Cancer Center provides promising evidence for an innovative combination treatment strategy that uses cells’ waste removal functions to effectively dismantle multiple myeloma. The findings, published recently in Cell Death & Disease, show how an experimental targeted protein degrader, developed in-house at the cancer center, enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs in preclinical models, while showing limited toxicity in cardiac models.

New research suggests that myotonia—the delayed relaxation of muscles that causes stiffness—may be more than a symptom of myotonic dystrophy type 1 (DM1). In animal models, eliminating myotonia improved muscle strength and muscle health.